You are here: Industry Insights > AML

News List

PLK1 Inhibitor PCM-075 Enhances Efficacy of a FLT3 inhibitor in Combination Therapy americanpharmaceuticalreview
August 17, 2017
Trovagene announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor.
FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800 pharmaceutical-technology
August 17, 2017
H3 Biomedicine, a member of Eisai’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used to treat patients with acute myelogenous leukaemia (AML) and
Green light for Celgene’s targeted AML drug pharmatimes
August 03, 2017
US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation
FDA Approves Idhifa drugs.com
August 02, 2017
FDA Approves Idhifa (enasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation
Boehringer's investigational anti-CD33 monoclonal antibody gains orphan drug designation for treatme cphi-online
March 15, 2017
BI 836858 was previously granted orphan drug designation for the treatment of patients with AML.
New drug combination gives hope for acute myeloid leukaemia treatment pharmafile
March 09, 2017
A new trial in the US hopes to marry a new pair of drugs as a combination treatment for acute ...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page